LONDON – The compelling clinical data and widespread interest in chimeric antigen receptor T-cell (CAR-T) immunotherapies is infecting regulatory agencies worldwide and they are vying to be first to review one of those products, according to Usman Azam, global head of cell and gene therapies at Novartis AG.